Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Primary Clinic (Direct GLP)

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Primary Clinic (Direct GLP) head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 186 · Grade C

Primary Clinic (Direct GLP)

Visit Primary Clinic (Direct GLP) Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 67 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Primary Clinic (Direct GLP) a bad call — it's best for readers who want glp-1 at wholesale cost inside a direct primary care membership. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
69
Transparency
90
88
Access Breadth
93
64
Clinical Oversight
92
77
Track Record
88
57
CoreAge RxBrief Score 94 · 67Primary Clinic (Direct GLP)

Price, coverage & the tracker

CoreAge RxPrimary Clinic (Direct GLP)
Brief Score94/100 (A)67/100 (C)
Semaglutide$149/moFrom $65/mo (0.25 mg dose, compounded)
Tirzepatide$349/moFrom $110/mo (2.5 mg dose, compounded)
CoverageAll 50 states10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Primary Clinic (Direct GLP): New to the tracker on 1 August 2026. The published line reads From $65/mo (0.25 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.